Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Melanoma 1Liver Neoplasms 1Head and Neck Neoplasms 1HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1HER2-positive Advanced Gastric Cancer 1HER2 Overexpression 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Letrozole 2Anastrozole 2trastuzumab deruxtecan 1dalpiciclib 1Vinorelbine 1Standard of Care 1Safety 1Radiotherapy 1In Situ Hybridization, Fluorescence 1Gonadotropin-Releasing Hormone 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Advanced Breast Cancer × trastuzumab deruxtecan × Clear all
NCT07180264 2025-11-18

Trastuzumab Deruxtecan in Advanced Breast Cancer

RenJi Hospital

Recruiting
118 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡